Products for Research Use Only
RegisterLogin

HL23

CAT: 0804-HY-155248-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-155248-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib and is more potent than Sorafenib+Vorinostat (HY-10221).
CAS Number
1448355-15-4
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hl23.html
Purity
99.64
Solubility
10 mM in DMSO
Smiles
CN([C@@]1([H])CC2=CC=C(OC)C(OC3=CC=C(C[C@]4([H])N(C)CC5)C=C3)=C2)CCC6=C1C(OC7=C(OC)C=C5C4=C7)=C(OC(C8=CC=CC=C8)=O)C(OC)=C6
Molecular Formula
C44H44N2O7
Molecular Weight
712.83
References & Citations
[1]Lu Y, et al. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma. J Adv Res. 2023 Sep;51:181-196.. .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-172097HL22
HY-P10875-01HL2-m5

Alternative Products

CatalogName
MBS5821069HL23
A24024-10HL23 10mg
A24024-50HL23 50mg
A24024-100HL23 100mg
A24024-5HL23 5mg

Popular Products